vaccines
An analysis published August 25 in the open-access journal PLoS Neglected Tropical Diseases sheds new light on the toll that neglected tropical diseases (NTDs) take on sub-Saharan Africa (SSA), with an estimated 500 million people suffering from these debilitating and sometimes deadly diseases. Helminth infections account for approximately 85% of the NTD burden.
BOSTON--Two of the most powerful approaches to cancer treatment -- a stem cell transplant and an immune system-stimulating vaccine -- appear to reinforce each other in patients with an aggressive, hard-to-control form of leukemia, Dana-Farber Cancer Institute scientists have found.
Research published by Army scientists indicates that a minor reduction in levels of one particular gene, known as CD45, can provide protection against two divergent microbes: the virus that causes Ebola hemorrhagic fever and the bacterium that causes anthrax.
We all know that influenza vaccination helps prevent disease, but a new study from Canada suggests it may also prevent another public health problem: inappropriate antibiotic use. The findings come from a new study in the September 1, 2009 issue of Clinical Infectious Disease, which is now available online.
WASHINGTON, Aug. 19, 2009 -- Good news for people fearful of needles and squeamish of shots: Scientists at the 238th National Meeting of the American Chemical Society report the design of a painless patch that may someday render hypodermic needles -- as well as annual flu shots -- a thing of the past.
WASHINGTON, Aug. 18, 2009 -- Scientists have used a new vaccine production technology to develop a vaccine for norovirus, a dreaded cause of diarrhea and vomiting that may be the second most common viral infection in the United States after the flu.
Prevention of H1N1 influenza virus through vaccination must be our top priority if disease patterns in the northern hemisphere follow those in the southern hemisphere this fall, writes Paul Hébert, Editor-in-Chief of CMAJ (Canadian Medical Association Journal) in an editorial http://www.cmaj.ca/press/cmaj091
WASHINGTON, Aug. 16, 2009 -- The first dry powder inhalable vaccine for measles is moving toward clinical trials next year in India, where the disease still sickens millions of infants and children and kills almost 200,000 annually, according to a report presented here today at the 238th National Meeting of the American Chemical Society (ACS).
Porcine circovirus associated diseases cost pig producers around the world hundreds of millions of dollars each year.
That's why Kansas State University virologists Dick Hesse and Bob Rowland have been working to create new vaccines to tackle such complex diseases.
Researchers at the Yerkes National Primate Research Center, Emory University, believe conventional vaccine strategies should not be the only avenue explored in the development of an effective AIDS vaccine.
Boston, Mass. -- Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).
PITTSBURGH, Aug. 4 -- Researchers at the University of Pittsburgh School of Medicine have learned that some healthy people naturally developed an immune response against a protein that is made in excess levels in many cancers, including breast, lung, and head and neck cancers. The finding suggests that a vaccine against the protein might prevent malignancies in high-risk individuals.
SEATTLE -- The latest drug regimens, vaccines and diagnostic tools under development to combat tuberculosis could have a potentially large impact on the disease once they become available, according to research findings published in the Aug. 3 early edition online of the Proceedings of the National Academy of Sciences.
"Money can't buy me love" the Beattles famously sang.
July 30, 2009 -- Researchers at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health are working with Argentina's National Institute of Infectious Diseases, the National Administration of Laboratories and Health Institutes (ANLIS), and Roche 454 Life Sciences to decode the complete genomic sequences of influenza pandemic (H1N1) 2009 virus from patie
